PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.39%
Revenue growth at 50-75% of MRVL's 14.60%. Martin Whitman would worry about competitiveness or product relevance.
12.03%
Gross profit growth similar to MRVL's 12.74%. Walter Schloss would assume both firms track common industry trends.
24.89%
EBIT growth below 50% of MRVL's 87.15%. Michael Burry would suspect deeper competitive or cost structure issues.
24.89%
Operating income growth under 50% of MRVL's 87.15%. Michael Burry would be concerned about deeper cost or sales issues.
20.16%
Net income growth under 50% of MRVL's 116.25%. Michael Burry would suspect the firm is falling well behind a key competitor.
19.05%
EPS growth under 50% of MRVL's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
19.05%
Diluted EPS growth under 50% of MRVL's 133.33%. Michael Burry would worry about an eroding competitive position or excessive dilution.
1.79%
Share count expansion well above MRVL's 1.92%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-1.12%
Reduced diluted shares while MRVL is at 5.58%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-1.76%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
28.75%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
1975.00%
Positive FCF growth while MRVL is negative. John Neff would see a strong competitive edge in net cash generation.
7.68%
10Y revenue/share CAGR under 50% of MRVL's 166.14%. Michael Burry would suspect a lasting competitive disadvantage.
22.96%
5Y revenue/share CAGR under 50% of MRVL's 166.14%. Michael Burry would suspect a significant competitive gap or product weakness.
61.53%
3Y revenue/share CAGR under 50% of MRVL's 166.14%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
45.01%
10Y OCF/share CAGR under 50% of MRVL's 543.89%. Michael Burry would worry about a persistent underperformance in cash creation.
48.79%
Below 50% of MRVL's 543.89%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-12.33%
Negative 3Y OCF/share CAGR while MRVL stands at 543.89%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
99.88%
Below 50% of MRVL's 570.43%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
21.43%
Below 50% of MRVL's 570.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
327.27%
3Y net income/share CAGR 50-75% of MRVL's 570.43%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
287.62%
10Y equity/share CAGR at 50-75% of MRVL's 567.97%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
68.15%
Below 50% of MRVL's 567.97%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-0.31%
Negative 3Y equity/share growth while MRVL is at 567.97%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
81.51%
Dividend/share CAGR of 81.51% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
-1.12%
Negative 5Y dividend/share CAGR while MRVL stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
1.53%
3Y dividend/share CAGR of 1.53% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
15.02%
AR growth well above MRVL's 14.27%. Michael Burry fears inflated revenue or higher default risk in the near future.
11.93%
Inventory shrinking or stable vs. MRVL's 29.09%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
1.68%
Asset growth well under 50% of MRVL's 5.88%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
1.11%
50-75% of MRVL's 1.70%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-4.70%
We’re deleveraging while MRVL stands at 7.94%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
4.05%
R&D dropping or stable vs. MRVL's 12.03%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
5.93%
SG&A growth well above MRVL's 0.48%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.